Elevated levels of circulating microRNA-200 family members correlate with serous epithelial ovarian cancer

BMC Cancer

Volumn 12, Issue , 2012, Pages

  Kan, Casina W S ^a   Hahn, Michael A ^a   Gard, Gregory B ^b   Maidens, Jayne ^b   Huh, Jung Yoon ^a   Marsh, Deborah J ^a   Howell, Viive M ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

^b ROYAL NORTH SHORE HOSPITAL   (Australia)

Author keywords

Biomarker; miR 103; miR 200; Serous ovarian cancer; Serum microRNA

Indexed keywords

MICRORNA; MICRORNA 103; MICRORNA 182; MICRORNA 200; MICRORNA 200A; MICRORNA 200B; MICRORNA 200C; MICRORNA 638; MICRORNA 92A; RNA; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BLOOD LEVEL; BLOOD VOLUME; CANCER CELL CULTURE; CANCER GRADING; CLINICAL ARTICLE; CONTROLLED STUDY; EPITHELIUM CELL; FEMALE; GENE EXPRESSION PROFILING; HUMAN; HUMAN CELL; OVARY CARCINOMA; RECEIVER OPERATING CHARACTERISTIC; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA EXTRACTION;

ADULT; AGED; AREA UNDER CURVE; CYSTADENOCARCINOMA, SEROUS; FEMALE; HUMANS; MICRORNAS; MIDDLE AGED; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; ROC CURVE; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL;

EID: 84872353766     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-12-627     Document Type: Article

References (37)

1. Tavassoli FA, Devilee P. World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of the Breast and Female Genital Organs 2003, Lyon: IARCPress.
2. Cannistra SA. Cancer of the ovary. N Engl J Med 2004, 351(24):2519-2529. 10.1056/NEJMra041842, 15590954.
3. Dodge JE, Covens AL, Lacchetti C, Elit LM, Le T, Devries-Aboud M, Fung-Kee-Fung M. Preoperative identification of a suspicious adnexal mass: A systematic review and meta-analysis. Gynecol Oncol 2012, 126(1):157-166. 10.1016/j.ygyno.2012.03.048, 22484399.
4. Drapkin R, von Horsten HH, Lin YF, Mok SC, Crum CP, Welch WR, Hecht JL. Human epididymis protein 4 (HE4) is a secreted glycoprotein that is overexpressed by serous and endometriold ovarian carcinomas. Cancer Res 2005, 65(6):2162-2169. 10.1158/0008-5472.CAN-04-3924, 15781627.
5. Ueland FR, Desimone CP, Seamon LG, Miller RA, Goodrich S, Podzielinski I, Sokoll L, Smith A, van Nagell JR, Zhang Z. Effectiveness of a multivariate index assay in the preoperative assessment of ovarian tumors. Obstet Gynecol 2011, 117(6):1289-1297. 10.1097/AOG.0b013e31821b5118, 21606739.
6. Ware Miller R, Smith A, DeSimone CP, Seamon L, Goodrich S, Podzielinski I, Sokoll L, van Nagell JR, Zhang Z, Ueland FR. Performance of the American College of Obstetricians and Gynecologists' ovarian tumor referral guidelines with a multivariate index assay. Obstet Gynecol 2011, 117(6):1298-1306. 10.1097/AOG.0b013e31821b1d80, 21555961.
7. Iorio MV, Visone R, Di Leva G, Donati V, Petrocca F, Casalini P, Taccioli C, Volinia S, Liu CG, Alder H, et al. MicroRNA signatures in human ovarian cancer. Cancer Res 2007, 67(18):8699-8707. 10.1158/0008-5472.CAN-07-1936, 17875710.
8. Nam EJ, Yoon HJ, Kim SW, Kim HG, Kim YT, Kim JH, Kim JW, Kim SH. MicroRNA expression profiles in serous ovarian carcinoma. Clin Cancer Res 2008, 14(9):2690-2695. 10.1158/1078-0432.CCR-07-1731, 18451233.
9. Yang H, Kong W, He L, Zhao JJ, O'Donnell JD, Wang J, Wenham RM, Coppola D, Kruk PA, Nicosia SV, et al. MicroRNA expression profiling in human ovarian cancer: miR-214 induces cell survival and cisplatin resistance by targeting PTEN. Cancer Res 2008, 68(2):425-433. 10.1158/0008-5472.CAN-07-2488, 18199536.
10. Wyman SK, Parkin RK, Mitchell PS, Fritz BR, O'Briant K, Godwin AK, Urban N, Drescher CW, Knudsen BS, Tewari M. Repertoire of microRNAs in epithelial ovarian cancer as determined by next generation sequencing of small RNA cDNA libraries. PLoS One 2009, 4(4):e5311. 10.1371/journal.pone.0005311, 2668797, 19390579.
11. Wang F, Zheng Z, Guo J, Ding X. Correlation and quantitation of microRNA aberrant expression in tissues and sera from patients with breast tumor. Gynecol Oncol 2010, 119(3):586-593. 10.1016/j.ygyno.2010.07.021, 20801493.
12. Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK, Pogosova-Agadjanyan EL, Peterson A, Noteboom J, O'Briant KC, Allen A, et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci USA 2008, 105(30):10513-10518. 10.1073/pnas.0804549105, 2492472, 18663219.
13. Cortez MA, Calin GA. MicroRNA identification in plasma and serum: a new tool to diagnose and monitor diseases. Expert Opin Biol Ther 2009, 9(6):703-711. 10.1517/14712590902932889, 19426115.
14. Chen X, Ba Y, Ma LJ, Cai X, Yin Y, Wang KH, Guo JG, Zhang YJ, Chen JN, Guo X, et al. Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res 2008, 18(10):997-1006. 10.1038/cr.2008.282, 18766170.
15. Taylor DD, Gercel-Taylor C. MicroRNA signatures of tumor-derived exosomes as diagnostic biomarkers of ovarian cancer. Gynecol Oncol 2008, 110(1):13-21. 10.1016/j.ygyno.2008.04.033, 18589210.
16. Hamilton TC, Young RC, McKoy WM, Grotzinger KR, Green JA, Chu EW, Whangpeng J, Rogan AM, Green WR, Ozols RF. Characterization of a Human Ovarian-Carcinoma Cell-Line (Nih-Ovcar-3) with Androgen and Estrogen-Receptors. Cancer Res 1983, 43(11):5379-5389.
17. Langdon SP, Lawrie SS, Hay FG, Hawkes MM, McDonald A, Hayward IP, Schol DJ, Hilgers J, Leonard RCF, Smyth JF. Characterization and properties of nine human ovarian adenocarcinoma cell-lines. Cancer Res 1988, 48(21):6166-6172.
18. Conover CA, Hartmann LC, Bradley S, Stalboerger P, Klee GC, Kalli KR, Jenkins RB. Biological characterization of human epithelial ovarian carcinoma cells in primary culture: the insulin-like growth factor system. Exp Cell Res 1998, 238(2):439-449. 10.1006/excr.1997.3861, 9473353.
19. Kalli KR, Chen BK, Bale LK, Gernand E, Overgaard MT, Oxvig C, Cliby WA, Conover CA. Pregnancy-associated plasma protein-A (PAPP-A) expression and insulin-like growth factor binding protein-4 protease activity in normal and malignant ovarian surface epithelial cells. Int J Cancer 2004, 110(5):633-640. 10.1002/ijc.20185, 15146551.
20. Ritchie ME, Silver J, Oshlack A, Holmes M, Diyagama D, Holloway A, Smyth GK. A comparison of background correction methods for two-colour microarrays. Bioinformatics (Oxford, England) 2007, 23(20):2700-2707.
21. Smyth GK, Michaud J, Scott HS. Use of within-array replicate spots for assessing differential expression in microarray experiments. Bioinformatics (Oxford, England) 2005, 21(9):2067-2075.
22. Smyth GK. Limma: linear models for microarray data. Bioinformatics and computational biology solutions using R and bioconductor 2005, 397-420. New York: Springer, Gentleman R, Carey V, Dudoit S, Irizarry R, Huber W.
23. Edgar R, Domrachev M, Lash AE. Gene expression omnibus: NCBI gene expression and hybridization array data repository. Nucleic Acids Res 2002, 30(1):207-210. 10.1093/nar/30.1.207, 99122, 11752295.
24. Wong L, Lee K, Russell I, Chen C. Endogenous controls for real-time quantitation of miRNA using TaqMan® MicroRNA Assays. Applied Biosystems Application Note 2007, Publication 127AP11-01:available at http://www.lifetechnologies.com.
25. Liu R, Chen X, Du Y, Yao W, Shen L, Wang C, Hu Z, Zhuang R, Ning G, Zhang C, et al. Serum MicroRNA expression profile as a biomarker in the diagnosis and prognosis of pancreatic cancer. Clin Chem 2012, 58(3):610-618. 10.1373/clinchem.2011.172767, 22194634.
26. Song J, Bai Z, Han W, Zhang J, Meng H, Bi J, Ma X, Han S, Zhang Z. Identification of suitable reference genes for qPCR analysis of serum microRNA in gastric cancer patients. Dig Dis Sci 2012, 57(4):897-904. 10.1007/s10620-011-1981-7, 22198701.
27. Resnick KE, Alder H, Hagan JP, Richardson DL, Croce CM, Cohn DE. The detection of differentially expressed microRNAs from the serum of ovarian cancer patients using a novel real-time PCR platform. Gynecol Oncol 2009, 112(1):55-59. 10.1016/j.ygyno.2008.08.036, 18954897.
28. Tanaka M, Oikawa K, Takanashi M, Kudo M, Ohyashiki J, Ohyashiki K, Kuroda M. Down-Regulation of miR-92 in Human Plasma Is a Novel Marker for Acute Leukemia Patients. PLoS One 2009, 4(5):e5532. 10.1371/journal.pone.0005532, 2678255, 19440243.
29. Peltier HJ, Latham GJ. Normalization of microRNA expression levels in quantitative RT-PCR assays: Identification of suitable reference RNA targets in normal and cancerous human solid tissues. RNA-Publ RNA Soc 2008, 14(5):844-852.
30. Davoren PA, McNeill RE, Lowery AJ, Kerin MJ, Miller N. Identification of suitable endogenous control genes for microRNA gene expression analysis in human breast cancer. BMC Mol Biol 2008, 9:76. 10.1186/1471-2199-9-76, 2533012, 18718003.
31. Reid G, Kirschner MB, van Zandwijk N. Circulating microRNAs: association with disease and potential use as biomarkers. Crit Rev Oncol Hematol 2011, 80(2):193-208. 10.1016/j.critrevonc.2010.11.004, 21145252.
32. Lodes MJ, Caraballo M, Suciu D, Munro S, Kumar A, Anderson B. Detection of cancer with serum miRNAs on an oligonucleotide microarray. PLoS One 2009, 4(7):e6229. 10.1371/journal.pone.0006229, 2704963, 19597549.
33. Leskela S, Leandro-Garcia LJ, Mendiola M, Barriuso J, Inglada-Perez L, Munoz I, Martinez-Delgado B, Redondo A, de Santiago J, Robledo M, et al. The miR-200 family controls {beta}-tubulin III expression and is associated with paclitaxel-based treatment response and progression-free survival in ovarian cancer patients. Endocr Relat Cancer 2011, 18(1):85-95.
34. Mateescu B, Batista L, Cardon M, Gruosso T, de Feraudy Y, Mariani O, Nicolas A, Meyniel JP, Cottu P, Sastre-Garau X, et al. miR-141 and miR-200a act on ovarian tumorigenesis by controlling oxidative stress response. Nat Med 2011, 17(12)):1627-1635.
35. Hu X, Macdonald DM, Huettner PC, Feng Z, El Naqa IM, Schwarz JK, Mutch DG, Grigsby PW, Powell SN, Wang X. A miR-200 microRNA cluster as prognostic marker in advanced ovarian cancer. Gynecol Oncol 2009, 114(3):457-46. 10.1016/j.ygyno.2009.05.022, 19501389.
36. Cochrane DR, Howe EN, Spoelstra NS, Richer JK. Loss of miR-200c: A Marker of Aggressiveness and Chemoresistance in Female Reproductive Cancers. Journal of oncology 2010, 2010:821717. 2798671, 20049172.
37. Park SM, Gaur AB, Lengyel E, Peter ME. The miR-200 family determines the epithelial phenotype of cancer cells by targeting the E-cadherin repressors ZEB1 and ZEB2. Genes Dev 2008, 22(7):894-907. 10.1101/gad.1640608, 2279201, 18381893.